The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?

Jeffrey M. Ryckman; Bradley N. Reames; Kelsey A. Klute; William A. Hall; Michael J. Baine; May Abdel-Wahab; Chi Lin

doi:10.1016/j.ctro.2021.04.002

The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?

Jeffrey M. Ryckman, Bradley N. Reames, Kelsey A. Klute, William A. Hall, Michael J. Baine, May Abdel-Wahab, Chi Lin

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Stereotactic Radiotherapy (SRT) over 5-15 days can be interdigitated without delaying chemotherapy. Bridging chemotherapy may allow for extended intervals to surgery, potentially improving sterilization of surgical margins and overall survival. SRT for pancreatic adenocarcinoma should not be limited to the tumor, and should consider hypofractionated approaches to regional nodes.

Original language	English (US)
Pages (from-to)	124-128
Number of pages	5
Journal	Clinical and Translational Radiation Oncology
Volume	28
DOIs	https://doi.org/10.1016/j.ctro.2021.04.002
State	Published - May 2021

Keywords

Pancreatic cancer
Stereotactic body radiotherapy
Total neoadjuvant therapy

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.ctro.2021.04.002

Cite this

@article{16a8e1438320457391946cc5b2361d57,

title = "The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?",

abstract = "Stereotactic Radiotherapy (SRT) over 5-15 days can be interdigitated without delaying chemotherapy. Bridging chemotherapy may allow for extended intervals to surgery, potentially improving sterilization of surgical margins and overall survival. SRT for pancreatic adenocarcinoma should not be limited to the tumor, and should consider hypofractionated approaches to regional nodes.",

keywords = "Pancreatic cancer, Stereotactic body radiotherapy, Total neoadjuvant therapy",

author = "Ryckman, {Jeffrey M.} and Reames, {Bradley N.} and Klute, {Kelsey A.} and Hall, {William A.} and Baine, {Michael J.} and May Abdel-Wahab and Chi Lin",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = may,

doi = "10.1016/j.ctro.2021.04.002",

language = "English (US)",

volume = "28",

pages = "124--128",

journal = "Clinical and Translational Radiation Oncology",

issn = "2405-6308",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer

T2 - Is it time for change?

AU - Ryckman, Jeffrey M.

AU - Reames, Bradley N.

AU - Klute, Kelsey A.

AU - Hall, William A.

AU - Baine, Michael J.

AU - Abdel-Wahab, May

AU - Lin, Chi

PY - 2021/5

Y1 - 2021/5

N2 - Stereotactic Radiotherapy (SRT) over 5-15 days can be interdigitated without delaying chemotherapy. Bridging chemotherapy may allow for extended intervals to surgery, potentially improving sterilization of surgical margins and overall survival. SRT for pancreatic adenocarcinoma should not be limited to the tumor, and should consider hypofractionated approaches to regional nodes.

AB - Stereotactic Radiotherapy (SRT) over 5-15 days can be interdigitated without delaying chemotherapy. Bridging chemotherapy may allow for extended intervals to surgery, potentially improving sterilization of surgical margins and overall survival. SRT for pancreatic adenocarcinoma should not be limited to the tumor, and should consider hypofractionated approaches to regional nodes.

KW - Pancreatic cancer

KW - Stereotactic body radiotherapy

KW - Total neoadjuvant therapy

UR - http://www.scopus.com/inward/record.url?scp=85104326512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104326512&partnerID=8YFLogxK

U2 - 10.1016/j.ctro.2021.04.002

DO - 10.1016/j.ctro.2021.04.002

M3 - Review article

C2 - 33981865

AN - SCOPUS:85104326512

SN - 2405-6308

VL - 28

SP - 124

EP - 128

JO - Clinical and Translational Radiation Oncology

JF - Clinical and Translational Radiation Oncology

ER -

The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this